In vitro characterization of PrismaLung+: a novel ECCO2R device

202022 citationsJournal Articlegold Open Access

Authors

Ingeborg Hospach · Baxter (Germany)

Jacques Goldstein · Baxter (Belgium)

Kai Harenski

John G. Laffey · Ollscoil na Gaillimhe – University of Galway

Dominique Pouchoulin · Baxter (France)

Manuela Raible · Baxter (Germany)

Stefanie Votteler · Baxter (Germany)

Abstract

The newly developed PrismaLung+ performed more effectively than PrismaLung, with performance of CO<sub>2</sub> removal comparable to A.L.ONE at the flow rates tested, despite the smaller membrane surface area of PrismaLung+ versus A.L.ONE. Clinical testing of PrismaLung+ is warranted to further characterize its performance.

Topics & Keywords

Mechanical Circulatory Support Devices Respiratory Support and Mechanisms Cardiac Arrest and Resuscitation

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Intensive Care Medicine Experimental

Volume 8, Issue 1, pp. 14-14

DOI: 10.1186/s40635-020-00301-7

Field-Weighted Citation Impact: 1.13